AnaptysBio, Inc. (ANAB)
45.95
-0.26
(-0.56%)
USD |
NASDAQ |
Oct 09, 16:00
46.00
+0.05
(+0.11%)
After-Hours: 20:00
AnaptysBio Net Income (Quarterly) : 229.24M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 229.24M |
| March 31, 2026 | -52.88M |
| December 31, 2025 | 49.61M |
| September 30, 2025 | 15.11M |
| June 30, 2025 | -38.63M |
| March 31, 2025 | -39.33M |
| December 31, 2024 | -21.78M |
| September 30, 2024 | -32.85M |
| June 30, 2024 | -46.66M |
| March 31, 2024 | -43.94M |
| December 31, 2023 | -42.21M |
| September 30, 2023 | -37.31M |
| June 30, 2023 | -39.84M |
| March 31, 2023 | -44.26M |
| December 31, 2022 | -26.41M |
| September 30, 2022 | -33.50M |
| June 30, 2022 | -32.55M |
| March 31, 2022 | -36.26M |
| December 31, 2021 | -32.54M |
| September 30, 2021 | -6.666M |
| June 30, 2021 | -0.429M |
| March 31, 2021 | -18.16M |
| December 31, 2020 | 33.65M |
| September 30, 2020 | -23.77M |
| June 30, 2020 | -21.55M |
| Date | Value |
|---|---|
| March 31, 2020 | -8.262M |
| December 31, 2019 | -20.26M |
| September 30, 2019 | -31.03M |
| June 30, 2019 | -23.96M |
| March 31, 2019 | -22.08M |
| December 31, 2018 | -16.99M |
| September 30, 2018 | -15.96M |
| June 30, 2018 | -13.62M |
| March 31, 2018 | -15.09M |
| December 31, 2017 | -6.861M |
| September 30, 2017 | -9.09M |
| June 30, 2017 | -2.684M |
| March 31, 2017 | -11.44M |
| December 31, 2016 | -4.259M |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.888M |
| March 31, 2016 | -0.888M |
| December 31, 2015 | -3.512M |
| September 30, 2015 | -1.462M |
| June 30, 2015 | -0.055M |
| March 31, 2015 | -0.376M |
| December 31, 2014 | -0.057M |
| September 30, 2014 | 0.717M |
| June 30, 2014 | 0.765M |
| March 31, 2014 | -1.193M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 2.375B |
| Anika Therapeutics, Inc. | 3.309M |
| BioCryst Pharmaceuticals, Inc. | 78.40M |
| Imunon, Inc. | -2.814M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 27.49M |
| Total Expenses (Quarterly) | -201.75M |
| EPS Diluted (Quarterly) | 6.185 |
| Enterprise Value | 1.471B |
| Earnings Yield | 14.03% |
| Operating Earnings Yield | 9.82% |
| Normalized Earnings Yield | 14.03 |